{"brief_title": "Alternate-Day Buprenorphine Administration. Phase IV - 5", "brief_summary": "The purpose of this study is to determine if three times a subject's daily maintenance dose will hold for 72 hours without changes in agonist and antagonist effects.", "condition": "Opioid-Related Disorders", "intervention_type": "Drug", "intervention_name": "Buprenorphine", "criteria": "Please contact site for information.", "gender": "All", "minimum_age": "20 Years", "maximum_age": "49 Years", "healthy_volunteers": "No", "id": "NCT00000223.xml"}